Tetra Bio Pharma Inc (OTCMKTS: TBPMF) in the Final Stages of Executing a Partnership With Avicanna Inc (OTCMKTS: AVCNF)

Tetra Bio Pharma Inc (OTCMKTS: TBPMF) recently announced the execution of a non-binding timesheet with Avicanna Inc  (OTCMKTS: AVCNF) to form a partnership with the latter. The term sheet will consist of calculated pillars such as the distribution of TBPMF’s products and AVCNF’s pharmaceutical ingredients.

The term sheet will also consist of the partnership’s efforts to support AVCNF’s pharmaceutical platform that receives the approval of Health Canada or the Food and Drug Administration (FDA). In addition, the partnership shall distribute some of TBPMF’s products along Avicanna’s network channels in South America at a low and effective cost.

Avicanna sells its cannabinoid products as an alternative form of medicine

Avicanna Inc is an organization that cultivates, develops, and commercializes cannabis-based products in the international market. The company also makes contributions in the medical and pharmaceutical fields, offering its cannabinoid products as an alternative to the common forms of medicine.

AVCNF’s headquarters are in Toronto, Canada, and most research is in the Johnson & Johnson Innovation Center in the Mars Discovery District. In addition, Avicanna partners with various academic and medical institutions in Canada, thus creating a highly regarded scientific platform that advanced various medical developments. Most of the developments done by the company include the commercialization of at least twenty of its products across the global market.

Avicanna’s products include cannabinoid-based beauty products and medical and wellness products. The company anticipates the partnership with Tetra as the two companies leverage their resources and obtain good results.

Tetra Bio Pharma’s operations 

Tetra Bio Pharma Inc is among the leading companies in the cannabis-derived drug discovery field and possesses the necessary licenses from the FDA and Health Canada. The two regulatory bodies recently approved TBPMF’s clinical program, whose goal was to create easy access to common prescription drugs and treatment therapies for physicians and their patients.

Tetra’s portfolio allowed it to create a platform of cannabis-derived products for several medical illnesses, such as oncology and others. In addition, the company focuses on offering its consumers concrete scientific research that regulates the appropriate TBS bodies. Tetra’s approach is to develop cannabis-related drugs that cater to certain illnesses.